Agreement has been reached for the provision of a new treatment for people with haemophilia, according to the Irish Haemophilia Society.
It will offer more protection against bleeding and instead of requiring vein access, it is injected under the skin (subcutaneously), once a week, or once every two weeks.
Brian O' Mahony, Chief Executive of the Irish Haemophilia Society, said that the new treatment will provide greater protection for people with haemophilia from the risk of bleeding and it will be much easier to administer without the need for regular intravenous injections.
The new treatment, Emicizumab (Hemlibra) is licenced by the European Medicines Agency.
Haemophilia is an inherited bleeding disorder, where one of the clotting factors is missing, or present in lower amounts.
The standard treatment for the past 40 years has been based on intravenous injections of the missing clotting factor.
In order to prevent joint damage, injections were administered three times per week.
In 2018, an improved form of the intravenous injection was introduced, which could be infused twice per week.
The product will be available to all people with the severe form of Haemophilia A, which is the most common type of the condition.
It has been made available following an agreement with the Haemophilia Product Selection and Monitoring Advisory Board, which procures medications for haemophilia in Ireland.
The board includes haemophilia specialists, the Irish Haemophilia Society and officials from the Department of Health.